<p>(A). Frequency of apoptosis of RPMI 8226 and AMO1. Left panels: dot plots showing the frequency of apoptosis at the indicated bortezomib (Bor.) concentrations (48 hr exposure). X-axis: cells stained with AnnexinV-PE. Y-axis: cells stained with 7-AAD. Right panels: bar graphs showing the % apoptotic cells (R1+R2) among examined cells treated with indicated concentration of bortezomib at 24 hr and 48 hr as indicated. Asterisks (*) indicate statistical significance: *0.01≤<i>P</i><0.05, **0.001≤<i>P</i><0.01, ***<i>P</i><0.001. NS: not significant. (B). Cell cycle analysis RPMI 8226 and AMO1 treated with 10 nM bortezomib (24 hr). DMSO served as the control. RPMI 8226 control (+DMSO): subG<sub>1</sub> 3.9%, G<sub>0</sub>/G<sub>1</sub> 48.3%,...
<p>(A) Viability assay evaluated by trypan blue exclusion was performed in BC3 (left panel) and BCBL...
<p>A. Inhibition of active sites was measured in cells immediately after 1-h of treatment with borte...
<p>A. Empty vector and GITR-transfected MM1.S cells were treated with Bortezomib for 48 hours. Cell ...
<p>Caspase-3 activity (A) and cleavage of PARP (B) were measured in extracts of cells treated with b...
<p>(A) Annexin V/PI double-staining flow cytometry of SKM-1 cells treated with 46.20 nM HHT, 4.46 nM...
<p>(A) Jurkat cells were pretreated with indicated concentrations of bortezomib (2.5–10 nM) for 24 h...
<p>(A) Dose-response curve of bortezomib sensitivity in representative cell lines. The vertical axis...
<p>HEK293T cells were treated with different concentrations of bortezomib and the levels of autophag...
<p>A) U87MG cells were seeded in a 96-well plate at a density of 10,000 cells per well. Cells were e...
<p>JJN3 DZNep-sensitive cells and LP1 DZNep-resistant cells were either treated with vehicle or DZNe...
Additional file 1: Figure S1. Bortezomib-mediated induction of early (Annexin +ive and PI −ive cells...
The objective of this study was to determine the changes in protein profiles of U-266 multiple myelo...
<p>U87MG cells were seeded in a 96-well plate at a density of 10,000 cells per well. Cells were pre-...
<p>PEL cells were exposed to Bortezomib, AG 490 or both for the indicated times, then resuspended in...
<p>JC1 staining and FACS analysis of MM cells (INA-6 or INA-6 cocoltured with HS-5 (A) or MCL cell l...
<p>(A) Viability assay evaluated by trypan blue exclusion was performed in BC3 (left panel) and BCBL...
<p>A. Inhibition of active sites was measured in cells immediately after 1-h of treatment with borte...
<p>A. Empty vector and GITR-transfected MM1.S cells were treated with Bortezomib for 48 hours. Cell ...
<p>Caspase-3 activity (A) and cleavage of PARP (B) were measured in extracts of cells treated with b...
<p>(A) Annexin V/PI double-staining flow cytometry of SKM-1 cells treated with 46.20 nM HHT, 4.46 nM...
<p>(A) Jurkat cells were pretreated with indicated concentrations of bortezomib (2.5–10 nM) for 24 h...
<p>(A) Dose-response curve of bortezomib sensitivity in representative cell lines. The vertical axis...
<p>HEK293T cells were treated with different concentrations of bortezomib and the levels of autophag...
<p>A) U87MG cells were seeded in a 96-well plate at a density of 10,000 cells per well. Cells were e...
<p>JJN3 DZNep-sensitive cells and LP1 DZNep-resistant cells were either treated with vehicle or DZNe...
Additional file 1: Figure S1. Bortezomib-mediated induction of early (Annexin +ive and PI −ive cells...
The objective of this study was to determine the changes in protein profiles of U-266 multiple myelo...
<p>U87MG cells were seeded in a 96-well plate at a density of 10,000 cells per well. Cells were pre-...
<p>PEL cells were exposed to Bortezomib, AG 490 or both for the indicated times, then resuspended in...
<p>JC1 staining and FACS analysis of MM cells (INA-6 or INA-6 cocoltured with HS-5 (A) or MCL cell l...
<p>(A) Viability assay evaluated by trypan blue exclusion was performed in BC3 (left panel) and BCBL...
<p>A. Inhibition of active sites was measured in cells immediately after 1-h of treatment with borte...
<p>A. Empty vector and GITR-transfected MM1.S cells were treated with Bortezomib for 48 hours. Cell ...